Abstract：Objective To analyze the role of serum cartilage oligomeric matrix protein (COMP) levels in differential diagnosis of rheumatoid arthritis (RA).Methods Eighty-two patients with RA and another thirty-four healthy control subjects were enrolled and divided into RA patients and healthy controls.According to clinical manifestations and results of laboratory examination, the patients were divided into active patients and patients in remission.According to the radiological changes,these patients were again divided into patients with joint bony damages and those without joint bony damage.The diagnostic ability of COMP for RA was evaluated by comparing it with anti-cyclic citrullinated peptide (anti-CCP) antibody levels.Receiver operating characteristic(ROC) curves were plotted before the areas under the ROC curves(AUC),while sensitivity and specificity were calculated.Results The serum COMP level was significantly higher in patients with RA than in control subjects(P<0.05), in active patients than in those in remission(P<0.05),and in patients with joint bony damages than in those without joint bony damage(P<0.05).When COMP and anti-CCP were used to distinguish between RA patients and healthy controls at the optimal cut-off value of 21.51 ng/ml and 34.76 RU/ml respectively, COMP’s AUC was (0.864), sensitivity (0.817) and specificity was (0.882), higher than those of anti CCP’s AUC (0.764), sensitivity (0.610) and specificity (0.824).Conclusions The serum COMP level can be used as a biological marker for cartilage destruction and for differentiating between patients with RA and healthy individuals.
Skoumal M, Kolarz G, Klingler A. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis[J]. Scandinavian Journal of Rheumatology, 2003, 32(3):156-161.
[2]
Garnero P,Piperno M,Gineyts E,et al.Cross sectional evaluation of biochemical markers of bone,cartilage,and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage[J].Ann Rheum Dis,2001,60(6):619-626.
[3]
Morozzi G, Fabbroni M, Bellisai F, et al. Cartilage Oligomeric Matrix Protein Level in Rheumatic Diseases[J]. Annals of the New York Academy of Sciences, 2007, 1108(1):398-407.
[4]
Aletaha D, Neogi T, Silman A J, et al. 2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum,2010, 62: 2569-2581.
[5]
Steinbrocker O, Traeger C H, Batterman R C. Therapeutic criteria in rheumatoid Arthritis[J]. J Am Med Assoc,1949; 140:659-662.
Sokka T, Kautiainen H, Toloza S, et al.QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen instandard rheumatology care in 15 countries[J].Ann Rheum Dis, 2007,66: 1491-1496.
Kaushik P, Kaushik R. Diagnosis and management of rheumatoid arthritis.[J]. American Journal of Medicine, 2008, 121(6):9-10.
[10]
Kim H J, Lee Y H, Kim C K. Changes in serum cartilage oligomeric matrix protein (COMP), plasma CPK and plasma hs-CRP in relation to running distance in a marathon (42.195 km) and an ultra-marathon (200 km) race[J]. European Journal of Applied Physiology, 2009, 105(5):765-770.
[11]
Mlbaek K,Hrslev-Petersen K,Primdahl J. Diagnostic delay in rheumatoid arthritis: a qualitative study of symptom interpretation before the first visit to the doctor[J]. Musculoskeletal Care,2016,14:26-36.
Fujikawa K,Kawakami A,Tamai M,et al.High serum cartilage oligomeric matrix protein determines the subset of patients with early stage rheumatoid arthritis with high serum C-reactive protein,matrix metalloproteinase-3,and MRI-proven bone erosion[J].J Rheumatol,2009,36(6): 1126-1129.
[14]
Andersson M L, Svensson B, Petersson I F,et al. Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis[J]. BMC sculoskelet Disord,2013,14:229.
[15]
Defrawy A O E, Gheita T A, Raslan H M, et al. Serum and synovial cartilage oligomeric matrix protein levels in early and established rheumatoid arthritis[J]. Zeitschrift Fur Rheumatologie, 2015, 74(Suppl 2):1-6.
[16]
Shen R, Ren X, Jing R, et al. Rheumatoid factor, anti-cyclic citrullinated peptide antibody, C-reactive protein, and erythrocyte sedimentation rate for the clinical diagnosis of rheumatoid arthritis[J]. Lab Med ,2015,46:226-229.
[17]
Shen R, Ren X, Jing R, et al. Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis.[J]. Laboratory Medicine, 2015, 46(3):226-229.
[18]
Nikolaisen C, Rekvig O P, Nossent H C. Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis[J]. Scandinavian Journal of Rheumatology, 2007, 36(2):97.
[19]
Bender A L, Da S I, von Mühlen C A, et al. High specificity but low sensitivity of the cartilage oligomeric matrix protein (COMP) test in rheumatoid arthritis and osteoarthritis[J]. Clinical Chemistry & Laboratory Medicine, 2010, 48(4):569-570.
[20]
Tseng S,Reddi A H,Di Cesare P E.Cartilage oligomeric matrix protein(COMP) : A biomarker of arthritis[J].Biomark Insights,2009,17(4):33-44.
2018, Vol. 29 
